Pascal Jezequel
Overview
Explore the profile of Pascal Jezequel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Jezequel P, Kerdraon O, Hondermarck H, Guerin-Charbonnel C, Lasla H, Gouraud W, et al.
Breast Cancer Res
. 2019 May;
21(1):65.
PMID: 31101122
Background: Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment of triple-negative breast cancer (TNBC), and therefore, molecular subtyping and identification of therapeutic pathways are...
22.
Jezequel P, Guette C, Lasla H, Gouraud W, Boissard A, Guerin-Charbonnel C, et al.
Proteomics
. 2019 Apr;
19(21-22):e1800484.
PMID: 30951236
Heterogeneity and lack of targeted therapies represent the two main impediments to precision treatment of triple-negative breast cancer (TNBC). Therefore, molecular subtyping and identification of therapeutic pathways are required to...
23.
24.
Das S, Romagnoli M, Mineva N, Barille-Nion S, Jezequel P, Campone M, et al.
Breast Cancer Res
. 2016 Apr;
18(1):40.
PMID: 27039296
Background: ADAM8 (a disintegrin and metalloproteinase 8) protein promotes the invasive and metastatic phenotype of triple-negative breast cancer (TNBC) cells. High ADAM8 expression in breast cancer patients is an independent...
25.
Vequaud E, Desplanques G, Jezequel P, Juin P, Barille-Nion S
Breast Cancer Res Treat
. 2015 Dec;
155(1):53-63.
PMID: 26679694
Survivin overexpression, frequently found in breast cancers and others, is associated with poor prognosis. Its dual regulation of cell division and apoptosis makes it an attractive therapeutic target but its...
26.
Jezequel P, Sharif Z, Lasla H, Gouraud W, Guerin-Charbonnel C, Campion L, et al.
BMC Med Genomics
. 2015 Nov;
8:80.
PMID: 26597277
Background: Breast cancer biological characteristics change as age advances. Today, there is a lack of knowledge regarding age-specific molecular alterations that characterize breast tumours, notably in elderly patients. The vast...
27.
Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N, et al.
Lancet Oncol
. 2015 Sep;
16(13):1324-34.
PMID: 26342236
Background: Molecularly targeted agents have been reported to have anti-tumour activity for patients whose tumours harbour the matching molecular alteration. These results have led to increased off-label use of molecularly...
28.
Campone M, Valo I, Jezequel P, Moreau M, Boissard A, Campion L, et al.
Mol Cell Proteomics
. 2015 Jul;
14(11):2936-46.
PMID: 26209610
To date, there is no available targeted therapy for patients who are diagnosed with triple-negative breast cancers (TNBC). The aim of this study was to identify a new specific target...
29.
Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W, et al.
Breast Cancer Res
. 2015 Apr;
17:43.
PMID: 25887482
Introduction: Triple-negative breast cancers need to be refined in order to identify therapeutic subgroups of patients. Methods: We conducted an unsupervised analysis of microarray gene-expression profiles of 107 triple-negative breast...
30.
Salas S, Jiguet-Jiglaire C, Campion L, Bartoli C, Frassineti F, Deville J, et al.
BMC Cancer
. 2014 Aug;
14:606.
PMID: 25146150
Background: The standard therapy regimen of conventional osteosarcoma includes neoadjuvant chemotherapy followed by surgical resection and postoperative chemotherapy. The percentage of necrotic tissue following induction chemotherapy is assessed by using...